Alpha-lipoic acid (ALA) is a compound your body makes that helps with energy-related enzyme activity. Human studies suggest it may reduce some symptoms of diabetic peripheral neuropathy, especially tingling, numbness, and burning, but it has not been shown to reverse nerve damage. Findings for blood sugar, weight, liver health, and other uses are mixed or small.
ALA is also called lipoic acid or thioctic acid. It occurs in foods in a protein-bound form, while supplements contain free ALA; Linus Pauling Institute explains that these are not the same form in the body.
Quick facts about alpha-lipoic acid
| Question | What human research shows |
|---|---|
| Forms | Studies used oral ALA, intravenous ALA, or both in sequence. Supplements may list R-ALA or a racemic R/S mixture. |
| Doses used in studies | Oral and intravenous studies in diabetic neuropathy used 600 to 1,800 mg per day. Other trials used 200 to 2,400 mg per day. |
| Typical study length | Neuropathy trials ranged from 3 weeks to 4 years. Metabolic trials ranged from 2 weeks to 1 year. |
| Main studied uses | Diabetic peripheral neuropathy, glucose-related measures, cardiometabolic measures, weight, fatty liver disease, and sperm measures. |
| Bottom line | The clearest human signal is symptom relief in diabetic peripheral neuropathy. Long-term effects on nerve function remain uncertain. |
What do human studies show?
Diabetic peripheral neuropathy
Diabetic peripheral neuropathy can cause burning, tingling, numbness, pain, or reduced feeling in the feet and legs. A 2026 neuropathy meta-analysis of 15 studies found that ALA improved several symptom measures, with the clearest results for tingling, numbness, and burning. The review reported that 600 mg per day was the dose most often linked with symptom improvement, while HbA1c and nerve-conduction outcomes were not consistently improved.
A separate 2026 network meta-analysis included nine randomized trials using 600 to 1,800 mg per day for 3 to 208 weeks. It found route mattered: intravenous ALA appeared to improve symptoms faster, while oral ALA had more consistent evidence for a lower-limb impairment score. The authors also found important bias concerns in the evidence for sequential intravenous-plus-oral treatment.
Results are not uniform. Oregon State University describes a four-year trial in 421 people with diabetic neuropathy in which 600 mg per day by mouth did not outperform placebo on the main combined measure of lower-limb impairment and nerve conduction, although some secondary measures improved. Its review also notes that many earlier neuropathy studies came from one research group and received manufacturer funding. This is why symptom relief is a more accurate takeaway than a claim that ALA restores or may help address neuropathy.
A symptom score is a surrogate outcome: a measured sign that may matter, but is not automatically the same as preventing falls, ulcers, disability, or other long-term outcomes.
Blood sugar and insulin resistance
The evidence is mixed. A 2026 cardiometabolic meta-analysis of 63 randomized trials found small average changes in insulin resistance, fasting glucose, HbA1c, body weight, BMI, and waist circumference, but no substantial effect on blood pressure, LDL cholesterol, or HDL cholesterol. The average weight change was 0.64 kg and the average BMI change was 0.27 kg/m², which are small effects.
Earlier trials summarized by Oregon State University found improved insulin sensitivity in some people with type 2 diabetes, including a 72-person trial using 600, 1,200, or 1,800 mg daily for four weeks. Yet a later 102-person placebo-controlled study using 600 mg daily for 16 weeks found no change in fasting glucose, insulin, or HOMA-IR, a calculation used to estimate insulin resistance. ALA is not a replacement for prescribed diabetes medicine.
Weight loss
ALA has produced modest average weight changes in some trials, not a large or reliable weight-loss effect. Oregon State University summarizes a 2018 meta-analysis that found small reductions in weight and BMI in people with higher BMI, with no reduction in waist circumference. The 2026 cardiometabolic meta-analysis also found a small average weight difference of 0.64 kg. The studies do not support naming ALA as a number-one supplement for neuropathy or weight loss.
Fatty liver disease
A 2026 fatty liver meta-analysis of seven randomized trials with 414 people with nonalcoholic fatty liver disease found no meaningful difference between ALA and placebo for liver enzymes, blood fats, glucose-related measures, body measures, or adipocytokines. The analysis found the same result across its subgroup analyses.
Sperm measures
A 2025 sperm-parameter meta-analysis of five randomized trials included 250 infertile men, with a mean follow-up of 3 months. It found improved total and progressive sperm motility and fewer abnormal sperm forms. It did not find a statistically significant difference in pregnancy rates, sperm concentration, live sperm, or ejaculation volume.
What doses did researchers use?
These are study doses, not a personal dosing recommendation.
| Research question | Form and dose studied | Duration | What was measured |
|---|---|---|---|
| Diabetic neuropathy symptoms | Oral or intravenous ALA, 600 to 1,800 mg/day | 3 to 208 weeks across trials | Symptoms, impairment scores, satisfaction |
| Short-term oral neuropathy trial | 600, 1,200, or 1,800 mg/day | 5 weeks | Neuropathic symptoms |
| Long-term diabetic neuropathy trial | 600 mg/day orally | 4 years | Lower-limb impairment and nerve conduction |
| Glucose utilization studies | 200 to 1,800 mg/day | 2 weeks to 1 year | Glucose, insulin, HbA1c, insulin resistance |
| Multiple sclerosis pilot study | 1,200 to 2,400 mg/day orally | 2 weeks | Safety and blood markers |
Most published human trials used a racemic mixture containing both R- and S-ALA. Oregon State University says human studies have not established which supplemental form is best. A label that says R-ALA therefore does not, by itself, tell you that the product matches the form or results of a specific trial.
What are the side effects and medicine interactions?
Oregon State University reports that oral ALA has generally had few serious side effects in clinical studies, including trials that used 600 mg per day for four years. Reported oral side effects include rash, hives, itching, abdominal pain, nausea, vomiting, diarrhea, vertigo, and malodorous urine at 1,200 mg per day. Nausea, vomiting, and vertigo increased with dose in one trial.
ALA may affect glucose handling. The Linus Pauling Institute notes a potential risk of low blood sugar when it is used with diabetes medicines. WebMD also lists diabetes medicines, thyroid medicines, chemotherapy, and medicines that slow blood clotting as medicines to discuss with a clinician or pharmacist before use; see its interaction overview.
A review in Nutrients describes reported cases of insulin autoimmune syndrome, a rare condition that can cause low blood sugar, in genetically susceptible people taking ALA. This is uncommon, but it is a useful reason to take unexpected low-blood-sugar symptoms seriously.
Who should talk to a clinician first?
- People using insulin or other medicines that lower blood sugar.
- People using thyroid medicine, chemotherapy, or medicines that affect blood clotting.
- People who are pregnant, breastfeeding, or considering ALA for a child.
- People with thyroid, kidney, or liver problems.
- Anyone with a history of a reaction to ALA, lipoic acid, thioctic acid, or an ingredient in the product.
This conversation is particularly important if you have diabetes or neuropathy symptoms. It is not a reason to stop, start, or change a prescribed medicine on your own.
What is still unknown?
ALA has not been shown to reverse neuropathy. The stronger trials focus on symptoms and scores rather than permanent repair of nerve damage or prevention of long-term complications. The time to notice a change also varies by study: intravenous trials measured improvement after about three weeks, while oral studies ran from weeks to years.
There is no head-to-head human evidence in this source pack that identifies CoQ10 or ALA as better for neuropathy. There is also no established human supplement dose for an ALA “deficiency.” Oregon State University describes deficiency as rare inherited problems in the body’s lipoic-acid pathway, not a routine nutritional deficiency.
Individual studies can point in different directions because they enroll different people, use different forms and doses, and measure different outcomes. A systematic review and meta-analysis combines studies, but its conclusion is only as dependable as the trials it includes.
How should you read an alpha-lipoic acid label?
- Amount: Compare the milligrams per serving with the dose and form used in the study you care about. A large number alone does not show a larger benefit.
- Form: Look for whether the label says R-ALA, S-ALA, racemic ALA, or simply alpha-lipoic acid. Human trials commonly used racemic ALA.
- Proprietary blends: If the label gives only a total blend amount, you cannot tell how much ALA it provides. Ask the seller for the amount before ordering.
- Other ingredients: Check the full supplement facts panel if you use medicines or have allergies. Other ingredients can matter as much as the ALA amount.
By ClinicalStudyConnect.com Research Desk